33 Swiss Pharmaceuticals & Biotech Stocks - Potentially Undervalued Companies - Investing Ideas

Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
GXI Gerresheimer	€75.60	0%	0%	€3.7b	€95.53	PE31.5x	E20.4%	1.2%
SDZ Sandoz Group	CHF32.02	0.09%	n/a	CHF13.8b	CHF36.46	PE195.4x	E29.5%	1.4%
NOVN Novartis	CHF91.74	-1.7%	3.2%	CHF187.2b	CHF98.82	PE22.5x	E10.0%	3.6%
TEVA Teva Pharmaceutical Industries	US$7.85	0%	0%	US$18.8b	US$8.29	PS1.2x	E40.4%	0%
1102657 GSK	UK£26.12	0%	-2.8%	UK£70.6b	UK£34.09	PE13.8x	E8.9%	5.7%
RO Roche Holding	CHF252.00	-2.4%	-19.9%	CHF186.0b	CHF306.07	PE16x	E8.7%	4.2%
ROG Roche Holding	CHF230.40	-2.8%	-20.7%	CHF186.0b	CHF279.83	PE16x	E8.7%	4.2%
ESF Eurofins Scientific	€505.00	0%	0%	€11.7b	€550.95	PE20.1x	E4.7%	1.7%
EVT Evotec	€27.76	0%	0%	€1.6b	€65.25	PS2x	E60.4%	n/a
943981 Johnson & Johnson	US$135.96	-2.9%	-2.9%	US$353.7b	US$159.59	PE20.7x	E6.9%	3.4%
BAYN Bayer	€190.00	0%	-5.0%	€27.1b	€253.78	PB0.8x	E49.1%	0.4%
BMY Bristol-Myers Squibb	US$54.24	0%	0%	US$83.6b	US$69.96	PS1.8x	E44.7%	5.8%
BIIB Biogen	US$222.00	0%	0%	US$31.7b	US$291.56	PE27.2x	E17.8%	n/a
2HQ Tilray Brands	US$46.28	0%	0%	US$1.5b	US$59.41	PS2.1x	E86.8%	n/a
NOVNEE Novartis	CHF91.75	-1.9%	2.7%	CHF187.2b	CHF98.83	PE22.5x	E10.0%	3.6%
VRX Bausch Health Companies	US$24.11	0%	0%	US$2.3b	US$37.10	PE-5.1x	E95.1%	n/a
TECN Tecan Group	CHF327.60	-1.7%	-8.1%	CHF4.2b	CHF395.57	PE31.8x	E9.2%	0.9%
J7Z Jazz Pharmaceuticals	US$104.98	0%	n/a	US$6.7b	US$179.05	PE20.2x	E18.6%	n/a
935700 Gilead Sciences	US$68.48	0%	10.5%	US$94.1b	US$82.84	PE17.2x	E7.8%	4.0%
QIA Qiagen	US$50.36	0%	0%	US$9.2b	US$61.37	PE27x	E11.3%	n/a
ADXN Addex Therapeutics	CHF0.069	1.8%	-45.1%	CHF8.9m	n/a	PS5.4x	E119.0%	n/a
MER Merck KGaA	€228.30	0%	n/a	€72.9b	€248.97	PE26.8x	E11.8%	1.3%
SANN Santhera Pharmaceuticals Holding	CHF9.36	1.2%	25.8%	CHF106.0m	CHF30.00	PE1.9x	n/a	n/a
OBSN ObsEva	CHF0.0012	0%	-98.3%	CHF140.6k	n/a	PE0.02x	n/a	n/a

Swiss Pharmaceuticals & Biotech Potentially Undervalued Companies